University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
David M. Jablons, MD

David M. Jablons, MD

Professor in Residence, Department of Surgery, UCSF
Ada Distinguished Professorship in Thoracic Oncology; Nan Tucker McEvoy Distinguished Professorship in Thoracic Surgical Oncology, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

I am the Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology at the University of California, San Francisco (UCSF). I am also Chief of General Thoracic Surgery, Program Leader of the Thoracic Oncology Program (TOP), and Director of the Thoracic Oncology Laboratory at UCSF. I oversee a thriving bench-to-bedside program at the UCSF Helen Diller Comprehensive Cancer, comprised of thoracic surgeons, thoracic oncologists, pulmonologists, radiation oncologists, and an array of other specialists.
The Thoracic Oncology lab utilizes state-of-the-art technology such as as next-generation sequencing (NGS), synthetic chemistry, and 3D-computer simulation for assessing drug efficacy. The TOP currently offers patients a broad menu of clinical trials, testing the most promising molecularly targeted agents. In 2005, I was awarded an NIH R01 grant to investigate the role of Wnt signaling in mesothelioma, and was awarded another R01 grant in 2008 to study the role of inflammation in lung carcinogenesis. The Thoracic Oncology lab has several areas of focus including molecular therapeutics, molecular diagnostics, systems biology, systems genetics, and bench-to-bedside drug discovery. The Thoracic Oncology Lab houses one of the largest thoracic tissue bank repositories in the US, with specimens for more than 1,300 patients including fresh/frozen matched tissue (tumor, normal, serum, pbmc) for lung cancer, mesothelioma, and other cancers.
I have been a pioneer in the field of molecular diagnostics, as part of a team that developed a multi-gene diagnostic assay identifying patients at risk for recurrence of early-stage non-small-cell lung cancer. I am also a co-investigator on several other grants as part of collaborations with lead PIs in other labs: (1) Development of new immunotherapy-based drugs for the treatment of lung cancer by isolating resident immune cells in lung tumor tissue to assess the adaptive immune response; (2) Investigation of the mechanism of the KMD5A protein in rendering NSCLC resistant to EGFR TKI therapy; and (3) Investigation of the role of genetic variation in TGF-beta overactivation in COPD.

Education

Yale College, BA, 1975-79, American Literature
Albany Medical Col. of Union U, MD, 1979-84
Naval Hospital, Intern, 1984-85, Surgery
Tufts University, Resident, 1985-86, Surgery
National Cancer Institute, National Institutes of Health, Fellow, 1986-89, Surgical Oncology
Tufts University, 1989-91, Surgery
Brigham & Women's Hospital, Fellow, 1992-92, Lung Transplantation
Cornell University Medical Center, Fellow, 1991-93, Surgery


Professional Experience

  • 1993-95
    Naval Medical Center, Attending, Cardiothoracic Surgery
  • 1994-95
    University of California, San Francisco School of Medicine, Assistant Clinical Professor, Cardiothoracic Surgery
  • 1995-00
    University of California, San Francisco School of Medicine, Assistant Professor, Cardiothoracic Surgery
  • 2000-04
    University of California, San Francisco School of Medicine, Associate Professor, Cardiothoracic Surgery
  • 2004-present
    University of California, San Francisco School of Medicine, Professor, Cardiothoracic Surgery
  • 2007-present
    University of California, San Francisco School of Medicine, Ada Distinguished Professor of Thoracic Oncology Surgery
  • 1986-89
    Fleet Hospital, Lieutenant, Medical Corps, USNR Staff Surgeon
  • 1989-91
    Fleet Hospital, Lieutenant Commander, Medical Corps,USNR Staff Surgeon
  • 1991-93
    Fleet Hospital, Lieutenant Commander, Medical Corps,USNR Staff Surgeon
  • 1997-present
    UCSF Medical Center, Chief, Section of General Thoracic Surgery

Selected Publications

  1. Woodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K. Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass. J Cardiothorac Surg. 2019 Sep 05; 14(1):158.
    View on PubMed
  2. Hsu PC, Jablons DM, Yang CT, You L. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci. 2019 Aug 05; 20(15).
    View on PubMed
  3. Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. J Biol Chem. 2019 Jul 24.
    View on PubMed
  4. Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 Jul 08.
    View on PubMed
  5. Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L. Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. Oncol Rep. 2019 Jun 20.
    View on PubMed
  6. Hung MS, Chen YC, Lin P, Li YC, Hsu CC, Lung JH, You L, Xu Z, Mao JH, Jablons DM, Yang CT. Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10. Cancers (Basel). 2019 May 02; 11(5).
    View on PubMed
  7. Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. J Thorac Oncol. 2019 Jul; 14(7):1223-1232.
    View on PubMed
  8. Lancaster EM, Jablons D, Kratz JR. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development. Genet Test Mol Biomarkers. 2019 Mar 22.
    View on PubMed
  9. Hsu PC, Yang CT, Jablons DM, You L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines. 2018 Dec 07; 6(4).
    View on PubMed
  10. Haro GJ, Seeley EJ, Jablons DM, Kratz JR. Central Airway Obstruction Due to Tracheal Glomus Tumor. Thorac Cardiovasc Surg Rep. 2018 Jan; 7(1):e43-e45.
    View on PubMed
  11. Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clin Lung Cancer. 2019 03; 20(2):e137-e141.
    View on PubMed
  12. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol. 2018 Sep; 13(9):1269-1283.
    View on PubMed
  13. Wang C, de Mochel NSR, Christenson SA, Cassandras M, Moon R, Brumwell AN, Byrnes LE, Li A, Yokosaki Y, Shan P, Sneddon JB, Jablons D, Lee PJ, Matthay MA, Chapman HA, Peng T. Expansion of hedgehog disrupts mesenchymal identity and induces emphysema phenotype. J Clin Invest. 2018 10 01; 128(10):4343-4358.
    View on PubMed
  14. Li T, Zhang W, Xu Q, Li S, Tong X, Ding J, Li H, Hou S, Xu Z, Jablons DM, You L. Transfer of multiple loci of donor's genes to induce recipient tolerance in organ transplantation. Exp Ther Med. 2018 Jun; 15(6):4961-4971.
    View on PubMed
  15. Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, Jablons DM, You L. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. J Cell Mol Med. 2018 06; 22(6):3139-3148.
    View on PubMed
  16. Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J, Dai Y, Yeh CC, Chan G, Liu S, Urisman A, Yang CT, Jablons DM, You L. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. J Cell Mol Med. 2018 Jun; 22(6):3073-3085.
    View on PubMed
  17. Tolani B, Hoang NT, Acevedo LA, Giroux Leprieur E, Li H, He B, Jablons DM. Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog. Oncotarget. 2018 03 06; 9(18):14311-14323.
    View on PubMed
  18. Giroux Leprieur E, Jablons DM, He B. Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies. Oncotarget. 2018 03 06; 9(18):14680-14691.
    View on PubMed
  19. Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y, Chan G, Huang Z, Hu B, Li H, Jablons DM, You L. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2017 Dec 29; 8(70):114576-114587.
    View on PubMed
  20. Wang L, Jin JQ, Zhou Y, Tian Z, Jablons DM, He B. Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma. Oncotarget. 2018 Jan 02; 9(1):853-865.
    View on PubMed

Go to UCSF Profiles, powered by CTSI